Search Results

Janux Therapeutics on Monday announced positive updated clinical data for both of its clinical programs in prostate cancer advanced or metastatic solid tumors.

Tourmaline Bio, Inc. announced the closing of its previously-announced underwritten public offering of 5,307,691 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 692,307 additional shares, at a public offering price of $32.50 per share.

Iovance Biotherapeutics, Inc. announced the closing of an underwritten public offering of 23,000,000 shares of its common stock at a public offering price of $7.50 per share.

Outlook Therapeutics, Inc. today announced that it has received written agreement from the FDA under an SPA for the NORSE EIGHT clinical trial protocol evaluating ONS-5010 in neovascular age-related macular degeneration (AMD) subjects.

Global Exosome Research Market is valued at US$ 172.30 Mn in 2023, and it is expected to reach US$ 570.70 Mn by 2031, with a CAGR of 16.26% during the forecast period of 2024-2031.

Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), and Jesse’s Journey, Canada’s leading charity fighting to defeat Duchenne, today announced a collaborative research award of $172,000 (CAD) in support of a two-year Clinical Fellowship in Duchenne Endocrinology and Bone Fragility.